Jan 19 2015
BMG Pharma S.r.l. (BMG) today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A. (Ferrer), granting them the rights to promote, sell and market its own product GelX® for the Middle East, Eastern Europe, Russia and North Africa.
The launch of GelX® will allow patients to receive the best care possible by using our innovative delivery technology to eliminate swallowing issues and discomfort associated with chemotherapy, radiotherapy, and related pharmacologic therapies.
"BMG's team are the inventors and generators of some of the major Rx devices in cancer palliative care and we are sure we are providing the market with a new generation of support for cancer patients," said Marco Mastrodonato, CEO of BMG.
"We are very pleased to be working with BMG on the launch of GelX® in these territories," said Antonio Villaró, COO of Ferrer. "We have been impressed by the innovation and efficacy of the GelX® delivery technology and look forward to providing significant improvements in the ease of use and compliance in patients with oral mucositis."
IFITM3 found to be critical regulator of immunotherapy sensitivity in small cell lung cancer